New smart drug takes aim at Hard-to-Treat cancers
NCT ID NCT06667960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called JK06, designed to seek out and attack cancer cells while sparing healthy ones. It is for adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU UCL Namur - site Godinne
RECRUITINGYvoir, Belgium
-
CUN Madrid
RECRUITINGMadrid, 28027, Spain
-
CUN Pamplona
RECRUITINGPamplona, 31008, Spain
-
Institut Jules Bordet
RECRUITINGBrussels, Belgium
-
Instituto de Investigación Sanitaria INCLIVA
RECRUITINGValencia, 46010, Spain
-
NEXT Oncology Barcelona
RECRUITINGBarcelona, Spain
-
Next Oncology Madrid
RECRUITINGMadrid, Spain
-
October 12th Hospital
RECRUITINGMadrid, 28041, Spain
-
START Barcelona
RECRUITINGBarcelona, Spain
-
START Madrid
RECRUITINGMadrid, Spain
-
START Rioja
RECRUITINGRioja, 26006, Spain
-
UZ Ghent
RECRUITINGGhent, Belgium
-
Universitair Ziekenhuis Antwerpen
RECRUITINGAntwerp, Belgium
-
Vall d Hebron Institute of Oncology VHIO
RECRUITINGBarcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?